NCT06152237: An ongoing trial by Taysha Gene Therapies, Inc.
This trial is ongoing. It must report results 3 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06152237 |
|---|---|
| Title | A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females With Rett Syndrome |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 12, 2023 |
| Completion date | Nov. 2, 2028 |
| Required reporting date | Nov. 2, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |